Prenetics Global (PRE) Projected to Post Quarterly Earnings on Thursday

Prenetics Global (NASDAQ:PRE) is anticipated to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $37.9030 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, February 18th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.22. Prenetics Global had a negative return on equity of 19.61% and a negative net margin of 61.33%.The company had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $36.15 million. On average, analysts expect Prenetics Global to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Prenetics Global Price Performance

Shares of Prenetics Global stock opened at $17.55 on Tuesday. The business has a 50-day moving average of $18.71 and a 200 day moving average of $17.03. Prenetics Global has a 12 month low of $5.10 and a 12 month high of $23.63. The stock has a market capitalization of $296.07 million, a price-to-earnings ratio of -4.37 and a beta of 0.15.

Prenetics Global declared that its Board of Directors has approved a share repurchase plan on Friday, March 6th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the company to repurchase up to 15.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts have commented on PRE shares. Wall Street Zen downgraded shares of Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Roth Mkm started coverage on shares of Prenetics Global in a research note on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price target for the company. Finally, Lake Street Capital started coverage on shares of Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Prenetics Global presently has an average rating of “Moderate Buy” and an average price target of $32.33.

Hedge Funds Weigh In On Prenetics Global

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN acquired a new position in shares of Prenetics Global in the fourth quarter worth $47,000. JPMorgan Chase & Co. acquired a new position in shares of Prenetics Global during the third quarter worth $65,000. Boothbay Fund Management LLC acquired a new position in shares of Prenetics Global during the fourth quarter worth $241,000. Jump Financial LLC acquired a new position in shares of Prenetics Global during the fourth quarter worth $268,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Prenetics Global during the fourth quarter worth $296,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.